Magnesium Carbonate
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Magnesium Carbonate: From Antacid Use to Active Peptic Ulcer Disease
One-Sentence Summary
Magnesium carbonate is an antacid that neutralizes gastric acid, although the US license records do not list an approved indication. The TxGNN model predicts it may be effective for active peptic ulcer disease. There are 0 registered clinical trials and 4 publications, and the publications are mostly older studies of antacid combinations.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the license data (known as an antacid) |
| Predicted New Indication | Active peptic ulcer disease |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 15 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, magnesium carbonate is an antacid that neutralizes gastric acid. Because peptic ulcers are acid-related, a link to ulcer healing is biologically plausible.
The published ulcer trials mostly test antacid/anticholinergic combinations or high-dose antacid regimens. The effect of magnesium carbonate alone cannot be isolated from them. The high TxGNN score probably reflects the existing use of antacids for acid-related conditions rather than a novel repurposing. This is better described as a label-adjacent use than a new one.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7034155 | 1981 | RCT | Scand J Gastroenterol | 72 patients with duodenal or prepyloric ulcer in a 12-week double-blind trial of cimetidine, antacid plus L-hyoscyamine, or placebo. Cimetidine healed 67% of ulcers at 3 weeks (p<0.005 vs placebo). The abstract is truncated, so the antacid arm’s result is not fully available. |
| 6755656 | 1982 | RCT | Scand J Gastroenterol Suppl | Antacid/anticholinergic vs cimetidine vs placebo in active prepyloric and duodenal ulcers. No abstract is available; it appears to be a companion report of the trial above. |
| 3003883 | 1985 | Clinical study (design not confirmed) | Scand J Gastroenterol | 80 patients with active duodenal ulcer were randomized to a high- or low-fiber diet. All received an antacid tablet four times daily. Healing was 67.5% vs 60%. This tests the diet, not the antacid. |
| 35720246 | 2022 | In vitro | Med Pharm Rep | Measured the acid-neutralizing capacity and other properties of antacids marketed in Morocco. It provides no clinical efficacy data. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not listed | Magnesia carbonica (Boiron) | Pellet | Not listed |
| Not listed | Magnesia Carbonica (Hahnemann Laboratories, Inc.) | Pellet | Not listed |
| Not listed | Magnesia carbonica (Boiron) | Pellet | Not listed |
| Not listed | Magnesia Carbonica (Hahnemann Laboratories, Inc.) | Pellet | Not listed |
| Not listed | Magnesia Carbonica (Hahnemann Laboratories, Inc.) | Pellet | Not listed |
The five entries above are 5 of 15 licenses. The product names, manufacturers and pellet form suggest homeopathic preparations rather than conventional antacid products. Other records include suspension and soluble-tablet (oral) forms.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials are registered for this indication, and the supporting papers are mostly 1980s studies of antacid combinations. These predate PPIs and H. pylori eradication, and none isolates magnesium carbonate as a single agent. Package insert safety information is also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications
- Mechanism of action data (MOA)
- Evidence for magnesium carbonate as a single agent, or a clear identification of its contribution within combination products
- Comparison against current standard care (PPIs and H. pylori eradication)
- Clarification of the approved indications and formulations of the 15 US licenses, given that the listed products appear homeopathic
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.